Treating Active TED
Thyroid eye disease may have met its match in teprotumumab
Lauren Robertson | | Quick Read
Recently presented Phase III clinical data show that teprotumumab significantly reduces double vision and improves the quality of life among patients with active thyroid eye disease (TED). Also known as Graves’ ophthalmopathy, the progressive autoimmune disease attacks the tissues behind the eyes (causing them to bulge outwards) and the muscles in the eyes, which become inflamed and scarred. Not only can the disease cause significant visual impairment, leading to a reduced ability to perform daily tasks, but the resulting changes in patients’ appearance can also affect mental health (1, 2).
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.